Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients. by Pieraerts, C. et al.
©
20
12
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
Detection of functional antigen-specific
T cells from urine of non-muscle invasive bladder
cancer patients
Claire Pieraerts, Virginie Martin, Patrice Jichlinski, Denise Nardelli-Haefliger* and Laurent Derré
Department of Urology; Centre Hospitalier Universitaire Vaudois; Lausanne, Switzerland
Keywords: bladder cancer, BCG therapy, T cells, IFNc ELISPOT
Abbreviations: BCG, Bacillus Calmette-Guérin; ELISPOT, enzyme-linked immunosorbent spot; IFNc, interferon c;
NMIBC, non-muscle invasive bladder cancer; PHA, phytohaemagglutinin
To gain further insights into the role of T lymphocytes in immune responses against bladder tumors, we developed a
method that monitors the presence of functional antigen-specific T cells in the urine of non-muscle invasive bladder
cancer patients. As relatively few immune cells can usually be recovered from urine, we examined different isolation/
amplification protocols and took advantage of patients treated with weekly intravesical instillations of Bacillus Calmette-
Guérin, resulting in large amounts of immune cells into urine. Our findings demonstrate that, upon in vitro amplification,
antigen-specific T cells can be detected by an interferon c (IFNc)-specific ELISPOT assay.
Introduction
Bladder cancer is the fourth and eight most common malignancy
in men and women, respectively. Seventy percent of bladder
cancers are diagnosed as non-muscle invasive, i.e., they are
confined to the mucosal or submucosal layer.1 However, 60–70%
of the tumors will recur, and according to stage and grade, 10 to
40% will progress to an invasive bladder cancer. Treatment of
advanced disease (i.e., muscle invasive bladder cancer) is based on
the complete resection of the bladder (cystectomy) combined with
chemotherapy or radiotherapy.1,2 The transurethral resection of
bladder tumors (TURB) in combination with intravesical
instillations of Bacillus Calmette-Guérin (BCG), an attenuated
strain of Mycobacterium bovis, has been the standard of care for
non-muscle invasive bladder cancer (NMIBC) patients since the
work of Morales et al.3 Intravesical BCG therapy has indeed
shown to reduce both recurrence and progression.4 BCG causes a
strong local inflammation, which generates a robust infiltration of
immune cells into the bladder wall and their accumulation in the
urine. An influx of granulocytes and mononuclear cells is induced
together with a Th1 cytokine profile, maturation of dendritic cell
(DC) and activation of natural killer cells.4,5 This robust influx of
cells involves not only cells from the innate immune system but
also lymphocyte populations, which appear to contribute to the
efficacy of BCG immunotherapy.6-8 Although BCG instillations
for superficial bladder cancer treatment constitute the most
successful immunotherapy on a large scale and are considered as a
standard treatment for this indication, repeated BCG administra-
tion are associated with significant toxicity. Moreover, resistance
occurs in 30 to 50% of cases, underlying the necessity for
alternative or complementary immunotherapy. Tumor associated
antigens (TAA) used as a vaccine to induce antitumor immune
responses are a promising strategy for treating different neoplasms
including bladder cancer, though with inconsistent clinical
efficacy to date. Vaccine responses are usually measured in the
blood, which may not reflect local antitumor T cells responses, de
facto hindering the optimization of immunotherapies.
Monitoring cellular immune responses against a broad array of
epitopes is complex, especially when limited testing material is
available and when patients are not selected for particular HLA-
types. In the case of bladder cancer, in order to better characterize
antitumor T-cell responses, it would be interesting to analyze the
specificity and the functionality of T cells present in patient’s
urine, which may reflect the T lymphocytes infiltrating bladder
tissue. One of the problem in this setting is that urine is a toxic
environment that influences T cells viability and functionality.9
To address these issues, we adapted techniques used to examine
lymphocytes in other tissue locations. We took advantage of urine
from NMIBC patients undergoing BCG treatment to maximize
the recovery of immune cells. Using in vitro expanded CD3+
lymphocytes or total cells purified from freshly recovered urine in
combination with an interferon c (IFNc)-specific ELISPOT
assay, we were able to detect, for the first time, functional antigen-
specific T lymphocyte responses from NMIBC patients. These
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techniques will be useful tools to monitor bladder cancer
immunotherapy trials.
BCG therapy increased the prevalence of T cells in the urine of
NMIBC patients. Although innate immune cells represent the
main type of effector cells infiltrating the bladder mucosa after
BCG instillations, some cells from the adaptive immune system,
notably T cells, can also invade bladder tissue and therefore be
found in the urine of patients throughout BCG therapy.6,10,11
We took advantage of samples obtained from patients with
different bladder cancer stages during an ongoing exploratory
study (named URO) approved by the local ethical committee,
and selected a subset of patients undergoing BCG instillations
and analyzed the presence of T cells in urine by flow cytometry.
Eleven patients diagnosed with NMIBC upon histological
analysis were recommended to receive BCG treatment according
to European guidelines. Most patients received six weekly
intravesical instillations of OncoTICE1 (MSD Merck Sharp
and Dohme AG). Urine was collected before and 4 h after BCG
treatment. In order to increase cell viability, urine samples (10–
500 ml) were processed within 2 h after urine collection
as follows. Samples were promptly supplemented with FCS
(30% v/v),9 then centrifuged and cells were resuspended in
RPMI 1640 medium supplemented with 10% FCS and
counted. As expected, we invariably observed a higher number
of total cells in the urine after BCG instillations as compared
with before the treatment (Fig. 1A). We also found an increase
in the total amount of cells recovered beyond the third BCG
instillation. Samples from nine patients were available for cell
cytometry analysis. To this aim, cells were stained with anti-
CD3 AF700 (Biolegend), anti-CD8 PE/AF610 (Invitrogen) and
anti-CD4 APC/H7 (PharMingen), followed by live/dead fixable
aqua stain (Invitrogen).12 As shown in Figure 1B, upon the
exclusion of dead cells and doublets, we determined the
percentage of ex vivo CD3+ cells and subsequently of CD8+
and CD4+ cells among CD3+ cells. While the proportion of
CD3+ T cells remained stable throughout BCG therapy (data
not shown), a regular increase in the absolute number of those
cells was observed both before and after BCG instillations
(Fig. 1C). Similar results were found when results were
normalized to the volume of each urine sample (data not
shown), suggesting that T cells progressively infiltrate bladder
tissue and are subsequently found in the urine of NMIBC
patients during BCG therapy.
In Vitro Expansion of Urine-Isolated T Cells
Since a low number of T cell was detected in the urine in
absence of BCG or at early time points of BCG therapy, we
decided to amplify them in vitro. Therefore, cells from the
available urine sample were directly stimulated in vitro (5  104
to 4  106 total cells) in presence of irradiated (3,000 rad)
allogenic PBMC (ratio: 1/1), and PHA (1 mg/ml) in RPMI
1640 medium supplemented with 8% human serum, 1%
penicillin/streptomycin, 1% non-essential amino acids, 1%
sodium pyruvate, β-mercaptoethanol and IL-2 (150 U/ml).13
Medium was changed every 2 d for 2 to 4 weeks, when
functional tests were performed. As shown in Table 1, out of 32
samples tested from seven patients, only about one third was able
to grow in culture when total urine cells were directly stimulated.
This poor rate of expansion was most likely due to the presence
of high number of granulocytes in the urine upon BCG
Figure 1. Ex vivo analysis of urine T cells during BCG therapy. (A) Mean +/2
SEM of the absolute number of total cells recovered from urine samples
before (white square) and after (black square) each BCG instillation
(n = 11 patients). (B) Representative example of ex vivo CD3, CD8 and CD4
staining of urine cells from one NMIBC patient before and after the sixth
BCG treatment. CD8 and CD4 dot plots are gated on CD3+ population.
(C) Mean +/2 SEM of absolute number of CD3 T cells from the analyzed urine
samples before (white square) and after (black square) each BCG instillation
(n = 9 patients).
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treatment,6,14,15 which rapidly die and release toxic compounds
during culture. In an attempt to remove these granulocytes, we
performed Percoll or Ficoll gradients. However, we were unable to
separate granulocytes from mononuclear cells (MNC), since
surprisingly almost all granulocytes remained in the MNC layer
after centrifugation. This is reminiscent of recently reported “low-
density” neutrophils that can be found among the PBMCs from
bladder, renal and lung cancer patients.16 As an alternative
purification method, we tested CD3+ magnetic sorting kit. CD3+
cells were primarily isolated from urine cells by magnetic sorting
according to manufacturer’s instructions (Dynabeads FlowComp
human CD3, 113–65D, Life Technologies) and subsequently
stimulated as described above. Between 14  106 and 300  106
total urine cells were sorted and 3  103 to 2  106 CD3+ cells
were obtained. Almost 82% of the 22 magnetically sorted samples
from six patients were expanded (Table 1). These results show
that T cells from the urine of bladder cancer patients may be
reliably expanded in vitro using ex vivo magnetic sorting prior to
culture. In contrast, only 31% of the urine samples cultured
without prior purification were amplified upon stimulation.
Next, we studied by flow cytometry the expression of CD3,
CD8 and CD4 in all samples that were successfully amplified in
culture from total cells (Fig. 2A) or from CD3+ sorted cells
(Fig. 2B). We found that all obtained populations are exclusively
CD3+, with a varying proportion of CD8 and CD4 cells among
them. Some samples had a predominance of CD4 T cells, while
others contained a higher proportion of CD8 T cells (Fig. 2). To
examine whether the permanence in culture influenced the T cell
type obtained, we plotted the ratio of CD8 and CD4 T cells
measured in the amplified CD3+ sorted populations against the
ratio measured in the corresponding ex vivo samples prior to
amplification (Fig. 2C). Our data shows that there is a significant
correlation between the CD8/CD4 ratio observed ex vivo and in
vitro (Spearman R = 0.83, p = 0.0004). However, we observed a
bias of in vitro expansion toward the population that was initially
outnumbered ex vivo (Fig. 2C). This suggests that despite in vitro
amplification was performed in the absence of specific antigens,
the frequency of antigen-specific T cells measured in amplified
urine T cells may not faithfully reflect the ex vivo frequency.
Detection of Pathogen-Specific T Lymphocytes
from Urine of Bladder Cancer Patients
Finally, we tried to detect the presence of antigen-specific T cells
in the expanded population from patient’s urine by an IFNc-
specific ELISPOT assay (human IFNc ELISPOT Kit,
856.051.020, Gen-Probe). In the absence of TAA vaccination,
we examined the T cell responses to pathogens to which most of
the patient have been exposed. As stimulating antigens, we used a
pool of 27 HLA Class I and II restricted epitopes derived from
different pathogens: Cytomegalovirus, Epstein Barr virus, influ-
enza virus and Clostridium tetani (CEFT pool PepMix, PM-
CEFT, JPT Technologies, see http://shop.jpt.com/images/Bild_
5/3_UK_datasheet%2Bceft%2Bpool.pdf). The test was per-
formed in nitrocellulose-lined 96-well plates (MultiScreen-HA
Table 1. Expansion of cells from urine of NMIBC patients. Cells from
available urine samples were stimulated in presence of allogenic irradiated
PBMC, 150 U/ml IL-2 and 1 mg/ml PHA, either directly after washing (n = 7
patients) or after CD3+ magnetic sorting (n = 6 patients)
Samples from urine Number of amplified samples
Total cells 10/32 (31.2%)
Sorted CD3+ cells 18/22 (81.8%)
Figure 2. Analysis of urine T cells expanded in vitro. (A and B) Percentage
of CD3+, CD3+CD8+ and CD3+CD4+ T cells after in vitro amplification
from total urine cells (A) or magnetically isolated T lymphocytes (B).
(C) CD8/CD4 ratio among CD3+ T cells from ex vivo samples (vertical axis)
were plotted against those obtained after in vitro amplification of CD3+
sorted T cells (horizontal axis). Spearman correlation R and p values are
indicated.
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sterile plate, MAHAS4510, Millipore). Briefly, plates were
coated overnight with antibody to human IFNc and washed
eight times with PBS 0.05% Tween-20. Then, 2  105, 1  105
and 0.5  105 urine-isolated cells were added in 200 mL RPMI
1640 medium supplemented with 10% FCS with or without 10
mg/mL peptide CEFT pool mix and incubated for 18 h at 37°C.
Assays were performed in duplicates. Then, cells were removed
and plates incubated with a second biotinylated antibody to
human IFNc and streptavidin-alkaline phosphatase. The spots
were revealed with BCIP/NBT substrate and counted. Results
with more than 30 background spots per 105 T cells were
considered invalid. In order to exclude false-positive results,
statistical analyses of IFNc ELISPOT responses were done using
the free website tool (http://www.scharp.org/zoe/runDFR)
developed by Moodie et al.17 Antigen presenting cells (APC)
were not added in this assay, because preliminary data using
autologous monocytic derived dendritic cells showed a high
background signal. Noteworthy, all T cells express HLA
molecules at their surface, allowing them to present exogenous
peptides and therefore serve as APC to the surrounding CD4 or
CD8 T cells.18
In vitro amplified samples obtained from NMIBC pre- and/or
post-BCG or pre-TURB, from total and CD3+ cells obtained
from four (URO3, 10, 11 and 30) and five patients (URO3, 5,
10, 15 and 30), respectively, were tested. Six out of seven samples
(two pre-BCG, one pre-TURB and four post-BCG) from
amplified total cells (Fig. 3A) and ten out of 12 samples (four
pre-BCG and eight post-BCG) from amplified CD3+ sorted cells
were specific for pathogen epitopes (Fig. 3B). Of note, three
samples of amplified total cells from patient URO30 and
six samples of CD3+ sorted cells from patient URO15 and
URO17 were removed from the analysis due to high background
(mean +/2 SEM of 157.4 +/2 44.8 spot / 105 cells in wells with
medium alone, data not shown). Thus, with both amplification
methods, about 30% of the CD3 cells yielded a too high
background to be analyzable by ELISPOT. Preliminary experi-
ments suggest that keeping amplified cells in culture for long time
(. 4 weeks) may help in decreasing IFNc secretion in the absence
of peptides. In two patients for whom multiple urine samples
were analyzed by ELISPOT, significant pathogen-specific T cell
responses were not always measured (i.e., 5/7 in URO3 and 1/2
in URO5, Figure 3). This may reflect local, intrabladder
variations in the T cell responses, highlighting the necessity and
relevance to determine immune responses at the site of the
tumor.19-21 However, a more comprehensive and longitudinal
analysis is needed in order to determine the variation of T cell
immune responses in the bladder upon BCG therapy and possibly
its correlation with systemic responses.
Altogether, our data demonstrate that antigen-specific T cells
isolated from the urine may be detected by IFNc-specific
ELISPOT assay, after in vitro amplification. However, our data
showed that total urine cells were hardly expanded in vitro as
compared with purified CD3+ T cells (Table 1). In addition,
when a low amount of cells (, 107 cells) is recovered, which is
often the case in early time points after BCG therapy or in pre-
BCG samples, magnetic isolation is not possible due to the low
proportion of CD3+ T cells. This limitation has to be considered
when trying to monitor antigen-specific T cells from the urine in
the absence of BCG treatment or at early time points after the
initiation of therapy. A solution may be to gather multiple urine
samples from a given patient to augment the probability to
achieve T cell amplification and thus IFNc ELISPOT analysis.
Finally, the massive accumulation of immune cells in urine due to
BCG is a unique opportunity to recover, without any invasive
surgery, cells that have potentially infiltrated tumor sites. This has
interesting implications for the monitoring of antigen-specific
therapies targeting T cells in superficial bladder cancer patients.
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Figure 3. Detection of antigen-specific T cells in the urine of NMIBC
patients. The presence of functional antigen-specific T lymphocytes was
assessed using an IFNc- specific ELISPOT assay on amplified total cells
(A) or amplified CD3+ sorted cells (B) as isolated from the urine of NMIBC
patients. Samples from each of the indicated URO patient correspond to
urines obtained at the specified pre- and/or post-BCG instillation or pre-
TURB time, after which T cells were expanded in vitro and tested by
ELISPOT. Number of IFNc secreting cells (spot)/105 cells are indicated
in presence of peptide (black bars) or medium alone (white bars).
Significant differences were calculated with the free website tool
(http://www.scharp.org/zoe/runDFR).17 p , 0.05 and p , 0.01 are
indicated by * and **, respectively.
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